Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 3—March 2006

Letter

"Mycobacterium tilburgii" Infections

Dirk Wagner*Comments to Author , Margreet C. Vos†‡, Anton G.M. Buiting‡, Annerose Serr*, Anneke M.C. Bergmans§, Winfried V. Kern*, and Leo M. Schouls¶
Author affiliations: *University Hospital, Freiburg, Germany; †Erasmus University Medical Center, Rotterdam, the Netherlands; ‡St Elisabeth Hospital, Tilburg, the Netherlands; §Franciscus Hospital, Roosendaal, the Netherlands; ¶National Institute of Public Health and the Environment, Bilthoven, the Netherlands

Main Article

Table

Characteristics of patients with confirmed "Mycobacterium tilburgii" disease*

Sex (age, y) Immuno-suppression CD4 count (cell/μL) Disease manifestation Treatment (duration, mo) Diagnosed in Reference
F (45) No Normal Bladder, intestinal lymphnodes, stomach, ileum, colon Pyrazinamide, isoniazid, rifampin (5); ethambutol, ciprofloxacin, clarithromycin, rifampin (11); surgical resection The Netherlands This study
M (34) AIDS 37 Esophagus, duodenum Ethambutol, clarithromycin, rifabutin (5) Germany This study
M (35) AIDS 20 Duodenum, abdominal lymph nodes Ethambutol, clarithromycin, rifabutin (12†) Germany (9)
M (41) AIDS 17 Pulmonary nodules Surgical resection; ethambutol, ciprofloxacin, clarithromycin (6); ethambutol, clarithromycin (12‡) Germany (10)

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO